IRIS
BASSET, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 778
EU - Europa 530
AS - Asia 310
AF - Africa 4
SA - Sud America 2
OC - Oceania 1
Totale 1.625
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 774
IE - Irlanda 312
CN - Cina 245
FI - Finlandia 72
DE - Germania 65
IT - Italia 44
SG - Singapore 33
JP - Giappone 17
SE - Svezia 15
AT - Austria 8
IN - India 7
CA - Canada 3
CZ - Repubblica Ceca 3
CL - Cile 2
ES - Italia 2
FR - Francia 2
GR - Grecia 2
IR - Iran 2
KR - Corea 2
LU - Lussemburgo 2
MU - Mauritius 2
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
EG - Egitto 1
GB - Regno Unito 1
LT - Lituania 1
MX - Messico 1
MY - Malesia 1
PH - Filippine 1
SA - Arabia Saudita 1
SL - Sierra Leone 1
Totale 1.625
Salva come PNG Salva come JPEG
Città #
Dublin 310
Chandler 208
Ashburn 79
Helsinki 60
Nanjing 54
Beijing 50
Boardman 48
Princeton 35
Shanghai 35
Lawrence 34
Medford 31
Singapore 28
Wilmington 26
Nanchang 20
Pavia 20
Jacksonville 19
Munich 17
Tokyo 16
Changsha 15
Shenyang 15
Hebei 14
Piscataway 13
Tianjin 11
Jiaxing 10
New York 10
Dallas 8
Norwalk 7
Pune 7
Chicago 6
Tamm 6
Woodbridge 6
Fairfield 5
Hangzhou 5
Los Angeles 5
Milan 5
Redwood City 5
Seattle 5
Cagliari 4
Falkenstein 4
Vienna 4
Washington 4
Brno 3
Catania 3
Athens 2
Dongdaemun-gu 2
Fuzhou 2
Houston 2
Luxembourg 2
Newark 2
Ningbo 2
Palermo 2
Taizhou 2
Vinovo 2
Zhengzhou 2
Altoona 1
Andover 1
Ann Arbor 1
Baku 1
Baltimore 1
Brussels 1
Cairo 1
Cangzhou 1
Cervera del Rio Alhama 1
Clearwater 1
Clifton 1
Des Moines 1
Freetown 1
Haikou 1
Hanover 1
Jinan 1
Kish 1
Laurel 1
London 1
Manila 1
Markham 1
Nagold 1
Nova Milanese 1
Orange 1
Riyadh 1
Saint-Alexis-de-Matapedia 1
San Diego 1
San Francisco 1
Sassari 1
Selangor 1
Shiraz 1
Sydney 1
Toronto 1
Totale 1.325
Salva come PNG Salva come JPEG
Nome #
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 67
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 67
A patient with AL amyloidosis with negative free light chain results 59
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 58
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 54
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 54
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 52
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 51
Prognostication of survival and progression to dialysis in AA amyloidosis 50
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 48
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 47
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 46
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 46
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 45
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 43
A biomarker-based approach in management of AL amyloidosis: from risk assessment to tailored-treatment strategy 43
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 41
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 40
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 40
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 39
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 37
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 36
The lung in amyloidosis 35
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 35
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 35
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 31
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 31
null 30
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 30
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 29
null 29
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 29
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 29
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 28
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 27
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 27
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 27
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 26
A case of monoclonal gammopathy of renal significance 25
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 24
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 23
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 22
Treatment of AL amyloidosis with bendamustine: A study of 122 patients 21
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 18
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 15
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 11
Renal amyloidoses 7
null 6
Totale 1.713
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.999
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.999
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202062 0 0 0 0 0 0 2 0 1 28 14 17
2020/202168 8 0 2 3 1 5 3 17 25 2 0 2
2021/2022154 2 0 1 0 5 3 0 12 9 14 17 91
2022/2023698 59 62 11 31 46 56 13 35 351 3 21 10
2023/2024362 44 78 17 26 30 68 12 20 2 15 21 29
2024/2025131 27 57 9 28 10 0 0 0 0 0 0 0
Totale 1.713